Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events
The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …
Long-acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study
Background Long-acting bronchodilators, including long-acting beta 2-agonists (LABA) and
the anticholinergic tiotropium, are recommended as initial maintenance therapy in COPD …
the anticholinergic tiotropium, are recommended as initial maintenance therapy in COPD …
Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta …
M Yang, Y Li, Y Jiang, S Guo, JQ He… - European Respiratory …, 2023 - Eur Respiratory Soc
Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …
Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
S Corrao, G Brunori, U Lupo… - European Respiratory …, 2017 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory
disease and its prevalence is increasing worldwide, in both industrialised and developing …
disease and its prevalence is increasing worldwide, in both industrialised and developing …
Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease
P Rogliani, L Calzetta, MG Matera… - Expert Opinion on …, 2019 - Taylor & Francis
Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-
dimensional approach, taking into account both symptoms of the patient and the number of …
dimensional approach, taking into account both symptoms of the patient and the number of …
Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 …
C Li, W Cheng, J Guo, W Guan - International Journal of Chronic …, 2019 - Taylor & Francis
Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2–agonists
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …
Safety considerations with dual bronchodilator therapy in COPD: an update
MG Matera, P Rogliani, L Calzetta, M Cazzola - Drug safety, 2016 - Springer
Combining a long-acting β 2-agonist (LABA) with a long-acting anti-muscarinic agent
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
P Rogliani, MG Matera, J Ora, M Cazzola… - International journal of …, 2017 - Taylor & Francis
Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …
Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled …
JC Samp, MJ Joo, GT Schumock… - Annals of …, 2017 - journals.sagepub.com
Background: The recent approval of several fixed-dose combination long-acting β2-agonist
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …
Future concepts in bronchodilation for COPD: dual-versus monotherapy
D Singh, JF Donohue, IH Boucot… - European …, 2021 - Eur Respiratory Soc
Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …